Latest on Ultrasound Renal Denervation
Published: 22 June 2022
28m 37sPart 3 | Session 3 "How to build Interventional HTN Therapy/Practice": Joachim Weil
5m 12sPart 4 | Session 1 RADIANCE II Pivotal Trial
16m 20sPart 5 | Session 3 ACC 2021 – RADIANCE-HTN TRIO Trial Results with Ajay Kirtane
5m 47sPart 5 | Session 4 EuroPCR 2020 – Crossover Results From the RADIANCE-HTN SOLO Trial
4m 2sPart 1 | Session 1 The Science of Ultrasound Renal Denervation: Introduction Philipp Lurz, Michael Joner, Felix Mahfoud, Andrew Wu
9m 18sPart 1 | Session 2 Ultrasound Technology – Its Development and Unique Characteristics: Andy Wu Andrew Wu
15m 10sPart 1 | Session 3 Ultrasound Renal Denervation Preclinical Evidence: Dr Michael Joner Michael Joner
18m 36sPart 1 | Session 4 RDN Procedure with Ultrasound Technology: Prof Felix Mahfoud Felix Mahfoud
10m 14sPart 1 | Session 5 Panel Discussion: All Philipp Lurz, Michael Joner, Felix Mahfoud, Andrew Wu
15m 15sPart 2 | Session 1 The Paradise uRDN System: Dr Andrew Sharp Andrew SP Sharp
9m 57sPart 2 | Session 2 uRDN Clinical Evidence - What does this mean for the field?: Prof Felix Mahfoud Felix Mahfoud
21m 53sPart 2 | Session 3 How to build uRDN centre / therapy pathway: Prof Roland Schmieder Roland E Schmieder
19m 35sPart 3 | Session 1 Introduction and "Ultrasound RDN - Reviewing the Latest Clinical Results" : Atul Pathak Joost Daemen, Atul Pathak, Joachim Weil
Ultrasound Renal Denervation (uRDN) is an innovative therapy option for the treatment of uncontrolled hypertension. uRDN therapy is delivered in a minimally invasive procedure that may lower high blood pressure by treating overactive renal nerves with ultrasound energy.
This page provides an overview of uRDN technology and the latest evidence from its associated RADIANCE clinical program.
The PARADISETM System is Limited to Investigational Use Only in the United States. Approved for distribution in CE mark countries only.
What you will learn:
- How uRDN works and its potential benefits for patients suffering from uncontrolled hypertension
- The clinical evidence supporting uRDN and its implications for the field of hypertension
- The process for building a uRDN centre and therapy network
This page is designed for:
- Interventional cardiologists
- General cardiologists
- Hypertension specialists
- Interventional radiologists
More from this programme
The Science of uRDN
The Evidence for uRDN
From Proof to Practice – Treating Hypertension With uRDN
RADIANCE II Pivotal Trial for Paradise Ultrasound Renal Denervation System in Patients With Hypertension
Results From the Latest Clinical Trials
Patient Perspective & Provider Referral Development
Dr Joost Daemen is a senior interventional cardiologist at the Thorax Center, Erasmus MC, Rotterdam, NL. Dr Daemen obtained his degree in medicine at the Erasmus University Medical Center. He is actively involved in several drug-eluting stent trials and is Principal Investigator of four trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure, vasospastic angina and heart failure. Dr Daemen is a member of the editorial board of EuroIntervention and the Netherlands Heart Journal, member of Young ICIN, and has completed courses in biomedical statistics and device training.
Dr Atul Pathak is a Pharmacologist and Cardiologist. He is leading a clinical research team focusing on cardiovascular pathophysiology and clinical pharmacology and is affiliated to INSERM (National Institute of Medical Research).
Dr Pathak has been awarded by the ESC (Young Investigator Award), by the British Pharmacological Society and the French Society of Cardiology. He is also member of the French Association of Pharmacologists, the French Society of Hypertension and Cardiology, the American Society for Heart Failure. He is elected President of the Cardiovascular Pharmacology Working Group of the French Society of Cardiology. He has both academic and institutional commitments, among them participation at advisory board at AFSSAPS (French FDA) and HAS for the review of clinical trials protocol, assessment of benefit /risk ratio of drugs (marketed or under development) and medico-economic issues (regarding lipid or blood pressure lowering drugs).
Prof Joachim Weil is the Head of the Medical Department II - Cardiology and Angiology of the Sana Hospitals Lübeck. As a modern competence center, the Department of Cardiology and Angiology offers highly specialized medical services in addition to cardiological care. In addition, Sana Hospitals Lübeck cooperates closely with the University Hospital of Schleswig-Holstein.
Professor Joachim Weil is one of Germany's renowned experts in the treatment of cardiovascular diseases and has received the Focus Award "TOP Physician - Hypertension" several times. He has longstanding experience especially in the field of renal denervation and is head of the clinical research group.